NASDAQ · Biotechnology

Oruka Therapeutics, Inc. (ORKA) Stock

$82.11 +6.25% NASDAQ: ORKA Healthcare

Valuation

MetricValue
Price$82.11
Market Cap$4.95B
P/E Ratio-34.28
P/B Ratio4.78
P/S Ratio0.00
EPS (TTM)$-1.85
52-Week High$115.52
52-Week Low$18.19
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-20.76%
ROA-11.66%
ROCE-13.89%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio22.37

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-19.0M$-10.0M$-7.0M$-88.0M$-122.0M
Net Profit$-19.0M$-10.0M$-5.0M$-84.0M$-105.0M
EPS$-16.68$-8.27$-4.44$-4.99$-2.31
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$55.0M$43.0M$38.0M$396.0M$489.0M
Total Liabilities$4.0M$1.0M$1.0M$14.0M$17.0M
Cash$53.0M$42.0M$37.0M$62.0M$47.0M
Borrowings$0$0$0$1.0M$2.0M

Latest News

Oruka Therapeutics Insider Sold Shares Worth $846,180, According to a Recent SEC Filing MT Newswires · Jul 13, 2026 HMI Capital Pares Its Stake in AI Company nCino Barrons.com · Jul 10, 2026 Oruka Therapeutics Insider Sold Shares Worth $472,079, According to a Recent SEC Filing MT Newswires · Jul 2, 2026 H.C. Wainwright Keeps Buy Rating on Oruka (ORKA) After Apogee Acquisition News Insider Monkey · Jul 1, 2026 Oruka Therapeutics H2 ORKA-001 Data Could Further De-Risk Lead Program, UBS Says MT Newswires · Jul 1, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-19.0M$-11.0M—$-58.0M$-88.0M
Investing Cash Flow$0$0—$-330.0M$-97.0M
Financing Cash Flow$0$0—$0$0
Net Cash Flow$4.0M$-11.0M—$24.0M$-15.0M
Free Cash Flow$-19.0M$-11.0M$0$-58.0M$-88.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.63
EV / EBITDA-34.17
FCF Yield-1.98%
Quick Ratio38.51
Interest Coverage0.00
Return 1Y488.88%
Return 3Y589.21%
Return 5Y357.99%

Ownership

Insiders Held1.23%
Institutions Held89.70%
Institutions Float Held90.82%
Institutional HolderSharesReport Date
FMR, LLC7,431,4032026-03-31
Venrock Adviser, LLC4,148,4282026-03-31
Fairmount Funds Management LLC3,705,2622026-03-31
Blackrock Inc.3,527,0872026-03-31
Viking Global Investors, L.P.2,666,6902026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ACRSAclaris Therapeutics, Inc. $3.83 +1.06% -8.88 $534.91M 0.00%
ALMSAlumis Inc. $7.16 +2.73% -1.80 $883.77M 0.00%
ANABAnaptysBio, Inc. $45.95 -0.56% 7.19 $1.36B 0.00%
ATTOAttovia Therapeutics, Inc. $16.21 -0.61% -23.81 $697.52M 0.00%
CNTBConnect Biopharma Holdings Limited $0.87 -1.21% -1.05 $54.78M 0.00%

About Oruka Therapeutics, Inc.

Oruka Therapeutics, Inc. (ORKA) stock trades at $82.11 with a market capitalization of $4.95B. The stock is valued at a price-to-earnings (P/E) ratio of -34.28, price-to-book of 4.78, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $18.19 and $115.52, and currently trades 28.9% below its 52-week high.

On profitability, Oruka Therapeutics, Inc. generates a return on equity (ROE) of -20.76%, return on capital employed of -13.89%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides